October 4, 2022
Via: PharmaphorumAavantiBio, a precision genetic medicine company that was bankrolled by Solid’s rival Sarepta back in 2020, focuses on neuromuscular and cardiac rare diseases. Its key assets include product candidates for Duchenne muscular dystrophy (DMD), Friedreich’s ataxia, and BAG3 mediated dilated […]
March 30, 2023
March 28, 2023
March 23, 2023
March 16, 2023